A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics
Noriko Iwamoto(Shimadzu (Japan)), Takashi Shimada(Keio University), Kotoko Yokoyama(Shimadzu (Japan)), Akinobu Hamada(National Cancer Research Institute), Bernard A. Fox(Oregon Health & Science University), Yoshinobu Koguchi(Providence Portland Medical Center), Brian Piening(Providence College), William L. Redmond(Providence St. Vincent Medical Center), Eric Tran(Providence Portland Medical Center), Atsushi Yonezawa(Kyoto University Hospital)
Cited by 5
Related Papers
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
|Journal of Clinical Investigation|2004|1.4k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Longitudinal multi-omics of host–microbe dynamics in prediabetes
|Nature|2019|620
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
|European Journal of Cancer|2017|565